Center for Regenerative Medicine
Our center is currently conducting research into the generation of embryonic stem cells (ESCs) for the purpose of replacing or restoring damaged or diseased cells or tissues, and ESC-based treatments for severe disorders of the urea cycle.
Successful generation of ESCs for clinical trialEmbryonic stem cells have indefinite proliferative potential and differentiation potential towards any kind of cell, and are a promising source of healthy cells for patients with intractable childhood diseases for which there is no effective therapy. We aim to generate human ES cells in the development of new therapies for intractable childhood diseases.
ESC-based therapy for the treatment of severe urea cycle disordersUrea cycle disorders, such as deficiencies of ornithine transcarbamylase and carbamoyl phosphate synthetase I, have a poor prognosis. As an alternative treatment for these disorders, we are developing ESC-based therapy through the manufacture of hepatocytes from human ESCs. We aim to perform initial first-in-human trials after receiving approval from the Ministry of Health, Labour and Welfare, Japan.
Promotion of regenerative medicine through the use of human somatic stem cellsWe are currently investigating the clinical applications of mesenchymal stem cells that are distributed in the bone marrow, cord blood, umbilical cord, placenta, menstrual blood, and endometrium.